:quality(90))
Transforming promising drug candidates into life-changing medicines
Patient tumor biology drives every step of our process. From collection to target discovery and drug development, we are guided by one principle: translational relevance for high patient impact.
Therapeutic development Cancer drug discovery that stays close to the patient
Target validation and characterization provide the biological foundation for therapeutic development. Building on these insights, we advance promising biologics and small-molecule programs through development candidate discovery, optimization, and preclinical evaluation.
Leveraging clinically annotated patient samples, proprietary model systems, and disease-relevant assay platforms, we refine therapeutic concepts and select candidates with the greatest potential for clinical success. The most promising opportunities progress through our development pipeline independently or in partnership, supporting multiple routes toward clinical translation and patient impact.
:quality(90))
Hit and lead development
Biologics
- Normal-tissue de-risking
- Antibody specificity, competitive differentiation and functional characterization
- Modality guidance and functional testing of biomarkers
- Functional validation in patient-derived and healthy organoids
Small molecules
- Biophysics-driven virtual ligand screening
- Chemical synthesis of virtual hits
- Hit screening utilizing cell-free and cell-based assays
- Validation using patient-derived 2D/3D tumor models
Clinical strategy, informed early
Clinical success begins with identifying the patients most likely to benefit. As programs advance toward the clinic, our translational research capabilities and extensive clinical network help define biomarker-driven development strategies, refine patient selection, and guide key development decisions. By connecting disease biology with real-world clinical insights, we help maximize the potential for meaningful therapeutic impact.
:format(webp):quality(90))
Our global clinical network provides access to experienced clinical sites and the envisaged patients to execute clinical trial strategies.
Precision oncology
“Developing novel therapies is only part of the story. We want to get them to the right patients as quickly as possible.”